

Current as of the date July 31, 2018														
Fiscal year of designation (Heisei)	Fiscal year of designation	Date of designation	Designation number	Grant period (years)	Name of the regenerative medicine with a designation	Anticipated intended use or indications on the designation	Name of applicant receiving designation	Intended use and indications approved for manufacturing and marketing	Name of applicant obtaining approval for manufacturing and marketing	Date of approval for manufacturing and marketing	Name of product approved for manufacturing and marketing	Notes	Date of revocation of designation	<Status>
20	2008	2008/6/11	(20ki) No. 15	2	Non-autologous cell cultured corneal epithelial cell sheet	Repair of corneal epithelium or improvement of visual function of patients with symptoms of corneal epithelial cell dystrophy	ArBlast Co., Ltd.	-	-	-	-			
22	2010	2011/3/18	(23ki) No. 22	3	Human tissue for autologous transplantation	Rapid epithelialization of refractory erosions and ulcers in patients with epidermolysis bullosa	Japan Tissue Engineering Co., Ltd.	-	-	-	-			
25	2013	2013/12/12	(25yaku) No. 325		NPR-01	External fistulas due to Crohn's disease (including anal fistulas)	Nihon Pharmaceutical Co., Ltd.	-	-	-	-			
25	2013	2013/12/12	(25yaku) No. 326		JR-031	Acute graft-versus-host disease	Japan Chemical Research Co., Ltd.	-	-	-	-			
26	2014	2014/11/25	(26sai)No. 1	2	autologous cultured epidermis	JACE is applied onto the resection wounds of GCMN (giant congenital melanocytic nevi) in order to produce prompt epithelialization of wounds.	Japan Tissue Engineering Co., Ltd.	JACE is applied onto the resection wounds of GCMN (giant congenital melanocytic nevi) in order to close the wounds.	Japan Tissue Engineering Co., Ltd.	2016/9/29	JACE			Approved
26	2014	2015/3/25	(27sai)No. 2		EYE-01M	Corneal epithelial stem cell deficiency	Japan Tissue Engineering Co., Ltd.	-	-	-	-			
28	2016	2016/5/25	(28sai)No. 3		CTL019	CD19-positive B-cell acute lymphoblastic leukemia CD19-positive diffuse large B-cell lymphoma CD19-positive follicular lymphoma	Novartis Pharma K.K.	-	-	-	-			
29	2017	2017/7/10	(29sai)No. 4		G47Δ	Malignant glioma	Daiichi Sankyo Company, Limited	-	-	-	-	sakigake(27sai)No.2		